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Abstract: AIMS Aberrant expression of microRNAs (miRNAs) is frequent in various cancers including
gliomas. We aimed to characterize the role of miR-16-5p as a candidate tumour suppressor miRNA in
gliomas. METHODS Real-time PCR-based approaches were used for miRNA and mRNA expression
profiling of glioma and non-neoplastic brain tissues as well as glioma cell lines. Protein levels were
determined by Western blotting. In vitro analyses were performed following overexpression of miR-
16-5p, trichostatin A treatment, and siRNA-mediated knock-down of HDAC3 in glioma cells. Effects
of miR-16-5p on glioma cell viability, apoptosis and response to irradiation and temozolomide were
assessed. RESULTS Expression of miR-16-5p was reduced relative to control brain tissue in isocitrate
dehydrogenase (IDH)-mutant astrocytomas of World Health Organization (WHO) grades II, III, and
IV, and a subset of IDH-wildtype glioblastomas WHO grade IV. MiR-16-5p expression was lower in
IDH-mutant than in IDH-wildtype gliomas, and down-regulated in IDH-wildtype glioma lines. MiR-16-
5p overexpression reduced expression of important cell cycle and apoptosis regulators in glioma cells,
including CDK6, CDC25A, CCND3, CCNE1, WEE1, CHEK1, BCL2, and MCL1. In line, CDK6,
WEE1, CHEK1, BCL2, and MCL1 transcript levels were increased in WHO grade III or IV gliomas.
Trichostatin A treatment and HDAC3 knockdown in glioma cells induced miR-16-5p up-regulation and
reduced expression of its targets. Moreover, miR-16-5p overexpression inhibited proliferation and induced
apoptosis in various glioma cell lines and increased sensitivity of A172 glioma cells to irradiation and
temozolomide. CONCLUSION Reduced expression of miR-16-5p contributes to glioma cell proliferation,
survival, and resistance to cytotoxic therapy. This article is protected by copyright. All rights reserved.
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Aims: Aberrant expression of microRNAs (miRNAs) is frequent in various cancers including 
gliomas. We aimed to characterize the role of miR-16-5p as a candidate tumour suppressor 
miRNA in gliomas.
Methods: Real-time PCR-based approaches were used for miRNA and mRNA expression 
profiling of glioma and non-neoplastic brain tissues as well as glioma cell lines. Protein levels 
were determined by Western blotting. In vitro analyses were performed following 
overexpression of miR-16-5p, trichostatin A treatment, and siRNA-mediated knock-down of 
HDAC3 in glioma cells. Effects of miR-16-5p on glioma cell viability, apoptosis and response 
to irradiation and temozolomide were assessed. 
Results: Expression of miR-16-5p was reduced relative to control brain tissue in isocitrate 
dehydrogenase (IDH)-mutant astrocytomas of World Health Organization (WHO) grades II, 
III, and IV, and a subset of IDH-wildtype glioblastomas WHO grade IV. MiR-16-5p expression 
was lower in IDH-mutant than in IDH-wildtype gliomas, and down-regulated in IDH-wildtype 
glioma lines. MiR-16-5p overexpression reduced expression of important cell cycle and 
apoptosis regulators in glioma cells, including CDK6, CDC25A, CCND3, CCNE1, WEE1, 
CHEK1, BCL2, and MCL1. In line, CDK6, WEE1, CHEK1, BCL2, and MCL1 transcript levels 
were increased in WHO grade III or IV gliomas. Trichostatin A treatment and HDAC3 
knockdown in glioma cells induced miR-16-5p up-regulation and reduced expression of its 
targets. Moreover, miR-16-5p overexpression inhibited proliferation and induced apoptosis in 
various glioma cell lines and increased sensitivity of A172 glioma cells to irradiation and 
temozolomide. 
Conclusion: Reduced expression of miR-16-5p contributes to glioma cell proliferation, 
survival, and resistance to cytotoxic therapy.
Abstract word count: 248 words































































Abbreviations used: CLL, chronic lymphocytic leukaemia; IDH, isocitrate 
dehydrogenase; miRNA, micro-RNA; pre-miR-16-5p, synthetic 
miR-16-5p precursor molecules; pre-miR-NC, synthetic negative 
control miRNA precursor molecules; TCGA, The Cancer Genome 
Atlas; TMZ, temozolomide; TSA, trichostatin A; 3’-UTR, 3’-
untranslated region; WHO, World Health Organization
































































Gliomas are the most common intrinsic brain tumours and comprise a spectrum of neoplastic 
lesions with distinct molecular and histological features, biological behaviour, and clinical 
outcome. The prognosis of glioma patients depends on tumour type and grade according to 
the World Health Organization (WHO) classification of tumours of the central nervous system 
(1), as well as on clinical parameters such as patient age, clinical performance status, and 
extent of tumour resection (2). In addition, molecular biomarkers have been identified that 
are linked to prognosis and/or response to cytotoxic therapy, such as mutations in the 
isocitrate dehydrogenase (IDH) genes IDH1 or IDH2, co-deletion of chromosomal arms 1p 
and 19q, and O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation (3), 
with IDH mutation and 1p/19q codeletion serving as novel diagnostic molecular biomarkers in 
the WHO classification 2016 (1). IDH-wildtype glioblastoma is the most common and most 
malignant glioma entity that requires up-front multimodal therapy consisting in surgical 
resection followed by radiotherapy with concomitant and maintenance temozolomide (TMZ) 
as the current standard of care (2, 4). Despite this aggressive treatment, glioblastomas 
invariably relapse and become resistant to radio- and chemotherapy. This in turn limits the 
prognosis to median overall survival times of approximately 16 months in clinical trials and 
less than 12 months in population-based studies (2). Therefore, it is of paramount 
importance to better understand the molecular mechanisms driving glioma growth and 
underlying radio- and chemotherapy resistance in order to develop more effective therapeutic 
strategies.
Here, we addressed the role of a specific microRNA (miRNA), miR-16-5p, in glioma 
pathogenesis and therapy resistance. MiRNAs are small, non-coding RNAs that regulate 
gene expression preferentially by binding to the 3´-untranslated region (3'-UTR) of mRNAs in 
a sequence specific manner, thereby leading to inhibition of translation and/or enhanced 
mRNA degradation (5, 6). Altered miRNA expression, including down-regulation of tumour 































































suppressive and up-regulation of tumour promoting miRNAs, have been identified in many 
cancers (6), including gliomas (7–9). Among the first miRNAs implicated as tumour 
suppressors was miR-16-5p, which belongs to a family of evolutionary conserved miRNAs 
that share a common seed sequence. MiR-16-5p is transcribed from two miRNA clusters on 
different chromosomes (10, 11). The miR-15b-16-2 cluster is located on chromosome 3 
intronic to the SMC4 gene, while the miR-15a-16-1 cluster is located on chromosome 13 
intronic to the DLEU2 gene (12, 13). The latter cluster is frequently affected by deletions in 
chronic lymphocytic leukaemia (CLL) (14). 
Using stem-loop reverse transcription PCR-based expression profiling of 79 astrocytic 
gliomas, we identified reduced levels of miR-16-5p expression in IDH-mutant astrocytic 
gliomas and a subset of IDH-wildtype glioblastomas relative to non-neoplastic brain tissue. 
Subsequent molecular and functional analyses provided further support for a role of 
miR-16-5p in regulating glioma cell proliferation and apoptosis, as well as modulating 
response of glioma cells to cytotoxic therapy.
Materials and methods
Human glioma tissue samples
Deep-frozen glioma tissue samples were retrieved from the tumour tissue bank at the 
Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany, and 
investigated as approved by the institutional review board (study number 3904). All tumours 
were classified according to the WHO classification of tumours of the central nervous system 
(1). Tissue samples used for nucleic acid extraction were histologically evaluated to assure 
an estimated tumour cell content of 80 % or more. We investigated tumour tissue samples 
from 79 patients, including seven patients with diffuse astrocytomas, IDH-mutant (WHO 
grade II), 10 patients with anaplastic astrocytomas, IDH-mutant (WHO grade III), 10 patients 































































with glioblastomas, IDH-mutant (WHO grade IV), and 52 patients with glioblastomas, IDH-
wildtype (WHO grade IV). Ten commercially available RNA samples from non-neoplastic 
human brain tissues (Ambion, Austin, TX; BioChain, Hayward, CA; Clontech, Mountain View, 
CA; Stratagene, Cedar Creek, TX) were used as normal tissue reference samples. The IDH 
mutation status of each tumour was determined by sequencing of the regions encoding IDH1 
codon 132 and IDH2 codon 172 (15, 16).
Glioma cell lines
A172, T98G, U251MG, U138MG, and U87MG cells were purchased from American Type 
Culture Collection (Manassas, VA, USA). TP365MG cells were provided by Dr. V. P. Collins 
(Cambridge, UK). Genotyping was performed at the Leibniz Institute DSMZ – German 
Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) for authentication 
of each cell line. Glioma cells were grown as monolayer cultures in Dulbecco´s modified 
Eagle´s medium (Life Technologies, Darmstadt, Germany) supplemented with 10 % heat-
inactivated fetal calf serum and 1 % penicillin G/streptomycin at 37°C and 5 % CO2 in a 
humidified incubator. RNA was extracted from cultured glioma cells using the TRIzol reagent 
(Life Technologies).
Real-time reverse transcription PCR analyses 
Expression profiling of 79 astrocytic gliomas and 9 non-neoplastic brain samples for 
differential expression of 365 miRNAs was performed on an ABI PRISM 7900HT system 
using TaqMan® Array MicroRNA cards with dye-labelled TaqMan® probes to monitor 
amplification (Life Technologies, Foster City, CA). Fluorescent data were converted into 
cycle threshold measurements by the SDS system software and exported to Microsoft Excel. 































































Four miRNAs (miR-30a-5p, miR-30b, miR-30c, miR-30d) with stable expression across the 
data set were used as reference for data normalization by SLqPCR (17). 
Targeted expression analyses of miR-16-5p in glioma cell lines were performed on a 
StepOnePlusTM Real-Time PCR system (Life Technologies) using the miRCURY LNATM 
Universal RT microRNA PCR kit and LNATM-enhanced PCR primers (Exiqon, Vedbaek, 
Denmark, miR-16-5p #205702). Fold expression changes relative to a calibrator sample 
(Universal Human Reference RNA, Stratagene, Cedar Creek, TX) were calculated with the 
2 -Ct method (18) using U6 snRNA (Exiqon, #203907) as reference. Expression of 
miR-16-5p target genes was determined by real-time reverse transcription-PCR using SYBR 
Green® (Life Technologies) incorporation and the StepOnePlusTM system with ARF1 (ADP-
ribosylation factor 1) as reference transcript. Each real-time PCR experiment was performed 
in technical duplicates. For primer sequences see Supplementary Table 1.
Microarray-based mRNA expression analyses 
Data on mRNA expression analyses of the miR-16-5p targets CDK6, CDC25A, CCND3, 
CCNE1, WEE1, CHEK1, BCL2, and MCL1 were retrieved from our published microarray 
data set obtained on 68 gliomas, including eight IDH-mutant diffuse astrocytomas, 10 IDH-
mutant anaplastic astrocytomas, 11 IDH-mutant glioblastomas, 39 IDH-wildtype 
glioblastomas, and four non-neoplastic brain tissue samples (16). 
Transient transfection of glioma cells 
A172, T98G, and TP365MG glioma cell lines were transiently transfected with 25 or 50 nM 
precursor-miR-16-5p molecules (pre-miR-16-5p, Ambion®, Life Technologies, #PM10339) for 
18 hours using LipofectamineTM 2000 reagent (Life Technologies). To control for unspecific 































































effects of transfection and to monitor transfection efficacy, glioma cells were transiently 
transfected with scrambled control oligonucleotides, i.e., Cy3-labelled precursor miRTM 
negative control (pre-miR-NC) (Ambion®, Life Technologies #AM17120). Overexpression of 
miR-16-5p in pre-miR-16-5p-transfected versus pre-miR-NC-transfected cells was 
determined by real time-reverse transcription PCR. 
Western blot analyses
Glioma cells were transiently transfected with 50 nM of pre-miR-16-5p or pre-miR-NC 24 
hours after seeding in 6-well culture plates, followed by protein extraction 72 hours post 
transfection. Cells were washed twice in ice-cold phosphate-buffered saline (PBS) buffer and 
lysed in RIPA buffer (1 x phosphate-buffered saline (PBS), 1 % Triton X-100, 0.5 % sodium 
deoxycholate, 0.1 % sodium dodecylsulfate) supplemented with one tablet of Complete 
Protease Inhibitor Cocktail Tablets and PhosSTOP Phosphatase Inhibitor Cocktail Tablets 
(Roche, Mannheim, Germany) per 10 ml of RIPA buffer. Cell lysates were centrifuged and 
protein concentration in the supernatant was determined with the Pierce BCA protein assay 
kit (Thermo Scientific, Rockford, IL). Twenty-five micrograms of total protein were separated 
by SDS-PAGE, followed by blotting to PROTRAN® BA83 nitrocellulose membranes 
(Schleicher & Schuell BioScience, Dassel, Germany). Membranes were blocked with 
Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, NE) followed by overnight incubation 
at 8°C with one of the following antibodies diluted in 1 x tris-buffered saline supplemented 
with 0.1 % Tween-20 (TBS-T): mouse anti-CDK6 (1:500; Cell Signaling, Danvers, MA; 
#3136), mouse anti-CCNE1 (1:500, Cell Signaling; #4129), mouse anti-CHEK1 (1:500, Cell 
Signaling; #2360), rabbit anti-BCL2 (1:500, Cell Signaling; #2870), rabbit anti-MCL1 (1:500, 
Cell Signaling; #4572), mouse anti-CDC25A (1:50, Santa Cruz Biotechnology, Dallas, TX; 
#sc-7389), mouse anti-WEE1 (1:50, Santa Cruz Biotechnology; #sc-5285), or mouse anti-
CCND3 (1:50, Dako, Glosttrup, DK; #M7156). A rabbit anti-ACTB antibody (1:1000, Abcam, 
Cambridge, MA; #ab8227) was used to detect expression of beta-actin as house-keeping 































































control. Western blots were washed in 1 x TBS-T followed by incubation with the appropriate 
secondary antibodies: IRDye 680RD goat anti-mouse IgG (1:10000, LI-COR; #926-68070), 
IRDye 800CW goat anti-rabbit IgG (1:10000, LI-COR; #926-32211), IRDye 800CW goat anti-
mouse IgG (1:10000, LI-COR; #926-32350), or IRDye 680RD goat anti-rabbit IgG (1:10000, 
LI-COR; #926-68071). Protein detection and quantification were performed using the 
Odyssey® Clx system (LI-COR). Each experiment was performed in triplicate.
Selection of predicted miRNA targets
Computational target prediction algorithms provided in Pictar (http://pictar.mdc-berlin.de/), 
and Targetscan 4.0 (http://www.targetscan.org) were used to select candidate targets of 
miR-16-5p. We specifically focused on targets involved in cell cycle and apoptosis regulation. 
3´-UTR luciferase reporter gene assays 
Parts of the 3´-untranslated regions (3'-UTRs) of WEE1, CHEK1, and MCL1 encompassing 
the predicted miR-16-5p binding sites were amplified by PCR from genomic DNA. Parts of 
the 3´-UTR of WEE1 or MCL1 carrying mutated miR-16-5p binding sites were synthesized by 
Eurofins Genomics (Ebersberg, Germany). Parts of the CHEK1 3´-UTR with mutated binding 
sites were generated by overlap extension PCR. Wildtype or mutant sequences were cloned 
between the XhoI and NotI restriction sites downstream of the Renilla luciferase coding 
sequence in the psiCHECKTM-2 vector (Promega, Mannheim, Germany). The psiCHECK™-2 
vector also contains the Firefly luciferase gene whose robust expression from a Herpes 
simplex virus tyrosine kinase (HSV-TK) promoter allows for normalization of Renilla 
luciferase expression. Each construct was verified by DNA sequencing. For luciferase 
reporter gene assays, T98G cells were cultured in 96-well plates and co-transfected with 
100 ng of psiCHECKTM-2 vector, either containing the wildtype or the mutated miRNA binding 































































sites, and 50 nM of pre-miR-16-5p or pre-miR-NC using LipofectamineTM 2000 reagent (Life 
Technologies). Forty-eight or 72 hours after transfection, Firefly and Renilla luciferase 
activities were measured using the Dual-Glo® Luciferase Assay System (Promega). 
Experiments consisted of five technical replicates and each transfection was repeated twice. 
For primer sequences see Supplementary Table 1.
Treatment of glioma cells with trichostatin A 
To screen for histone acetylation-dependent regulation of miR-16-5p expression, A172, 
T98G, TP365MG, and U138MG glioma cells were incubated 24 hours after seeding in 
medium containing 1 µM trichostatin A (TSA, Merck, Darmstadt, Germany) for 36 hours. 
Total RNA was then isolated from treated and untreated (control) cells using TRIzol® reagent 
(Life Technologies), followed by real time RT-PCR analysis for miR-16-5p expression. 
SiRNA-mediated knock-down of HDAC3 in glioma cells
T98G, U87MG or U251MG glioma cells were transiently transfected with 50 nM siRNA 
against HDAC3 (Qiagen; #SI00057316 and #SI00057337) using LipofectamineTM 2000 
reagent (Life Technologies). As control, cells were transiently transfected with Cy3-labelled 
negative control oligonucleotides (AllStars Negative siRNA Cy3, Qiagen; #1027281). Knock-
down of HDAC3 was verified by real time-reverse transcription PCR and Western blotting. All 
transfections were performed in three independent experiments.































































Analysis of viability, proliferation and caspase-3/7 activity in glioma cells
The viability of A172, T98G, and TP365MG glioma cells transfected with pre-miR-16-5p 
molecules compared to pre-miR-NC-transfected cells was determined 72 hours post 
transfection using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Mannheim, 
Germany). To analyse the effect of pre-miR-16-5p transfection on proliferation, the BrdU-
based cell proliferation chemiluminescent ELISA test (Roche Diagnostics, Mannheim, 
Germany) was used. Cells were harvested 72 hours post transfection and the BrdU labelling 
solution was added 12 hours before harvesting. Caspase-3/7 activity in pre-miR-16-5p 
transfected cells was determined 72 hours post transfection using the luminescence-based 
Caspase-Glo® 3/7 Assay System (Promega). A Beckman Coulter PARADIGM™ detection 
platform was used for measurement of luminescence or fluorescence signals. Each 
experimental group consisted of five replicates. Each assay was repeated twice. 
Determination of cell survival following irradiation or TMZ treatment 
The effect of miR-16-5p on response of glioma cells to irradiation or TMZ was investigated as 
reported (19). Briefly, T98G or A172 glioma cells were seeded at 300 cells per well in 96-well 
plates in triplicates, allowed to adhere overnight, and exposed to TMZ at defined 
concentrations, according to respective EC50 values of each cell line (20), for 24 hours in 
serum-free medium, followed by an observation period for 2-3 weeks in serum-containing 
medium until untreated control cells reached confluence. Cell density was assessed by 
crystal violet staining. TMZ (Schering-Plough, Kenilworth, NJ, USA) was prepared as a stock 
solution at 100 mM in dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO). For irradiation 
experiments, cells were irradiated in a 60-Co-radiation source (Gebrüder Sulzer, Thermische 
Energiesysteme, Winterthur, Switzerland) at defined doses in the range of 1 Gy – 9 Gy. The 
fraction of surviving cells following treatment was calculated in % relative to control cells.































































Association of miR-16-5p expression with molecular markers and overall survival 
Associations of miR-16-5p expression with IDH status and TP53 mutation, as well as overall 
survival of glioma patients were investigated by using The Cancer Genome Atlas (TCGA) 
datasets (http://cancergenome.nih.gov/). Expression data were downloaded directly from the 
GDC data portal (https://portal.gdc.cancer.gov/) and via the cBio Cancer Genomics Portal 
(www.cbioportal.org) (21, 22) using the open-source R package “cgsdr” (version 1.2.5) and 
the statistical computing language R (version 3.3.2). Published biomarker information on IDH 
status and 1p/19q codeletion status (23) was used to classify tumours according to the WHO 
classification (1). To investigate the association of miR-16-5p expression with patient 
survival, we divided the TCGA cohorts into patients with tumours showing low or high 
expression using the median level as cut-off. Survival data were obtained from a previous 
TCGA paper (23). Kaplan-Meier survival probability estimates were calculated using the R-
Package “Survival” (version 2.40-1).
Statistical analysis
Expression differences between glioma groups were analysed by two-sided Student´s t-test 
(two groups) or ANOVA and Dunnett's post-hoc test (multiple groups). Correlation of 
expression levels was analysed by calculating Pearson’s r and a corresponding p-value 
(t-test). Differences in overall survival between patient groups with high and low miRNA 
expression were investigated by calculating Kaplan-Meier survival curves and use of a 
logrank-test. Statistical analysis of luminescence (viability, proliferation) or fluorescence 
(caspase-3/7 activity) values derived from pre-miR-16-5p-transfected versus pre-miR-NC-
transfected cells of three independent experiments with five replicates per experimental 
group were analysed by a mixed model. Two-sided paired Student´s t-test was used to 
compare the mean luminescence values between pre-miR-16-5p- and pre-miR-NC-
transfected glioma cells in the luciferase reporter gene assay. TSA-treated glioma cells 































































versus control cells and siRNA-transfected versus control-transfected cells were compared 
using two-sided paired Student´s t-test. Cell survival assay results of treated samples were 
normalized to the respective untreated control values. Significance was assessed using two-
sided unpaired Student’s t-test. Differences or associations were considered as significant 
with p < 0.05.
Results
Reduced expression of miR-16-5p in astrocytic gliomas and glioma cell lines relative 
to non-neoplastic brain tissue
We performed miRNAs expression profiling of primary tumour samples from 79 patients with 
astrocytic gliomas of WHO grades II, III or IV using TaqMan® Array microfluid cards. 
Thereby, we identified reduced mean expression levels of miR-16-5p relative to non-
neoplastic brain tissue in IDH-mutant diffuse astrocytomas WHO grade II (AIImut, 5.6-fold 
reduced mean miR-16-5p expression, p<0.01), IDH-mutant anaplastic astrocytomas of WHO 
grade III (AAIIImut, 4.9-fold reduced mean miR-16-5p expression, p<0.01), and IDH-mutant 
glioblastomas of WHO grade IV (GBIVmut, 3.1-fold reduced mean miR-16-5p expression, p < 
0.05). In IDH-wildtype glioblastomas (GBIVwt), expression of miR-16-5p was more 
heterogeneous. Although mean expression in this group was not significantly lower as 
compared to the non-neoplastic brain tissue samples, 34 of 52 investigated tumours showed 
reduced expression levels relative to the median miR-16-5p expression in the control 
samples (Fig. 1A). MiR-16-5p expression was significantly lower in 27 IDH-mutant as 
compared to 52 IDH-wildtype gliomas of our cohort (Fig. 1B). We also investigated six IDH-
wildtype glioma cell lines (A172, T98G, U251MG, U138MG, U87MG, TP365MG) and found 
reduced miR-16-5p expression levels relative to non-neoplastic brain tissue samples (Fig. 
1C).































































Overexpression of miR-16-5p decreases glioma cell viability, reduces proliferation, 
and induces caspase-3/7 activity 
To determine the functional roles of miR-16-5p in glioma cells, we transiently overexpressed 
precursor molecules of miR-16-5p (pre-miR-16-5p) or respective non-targeting control 
oligonucleotides (pre-miR-NC) in three glioma cell lines (A172, T98G, and TP365MG), 
followed by determination of cell viability (Fig. 2A), proliferation (Fig. 2B) and caspase-3/7 
activity (Fig. 2C). Transfection of pre-miR-16-5p significantly decreased cell viability and 
proliferation in all three cell lines when compared to control-transfected cells. Caspase-3/7 
activity was significantly increased by pre-miR-16-5p transfection in the p53-wildtype A172 
and TP365MG cell lines but decreased in p53-mutant T98G cells. 
Overexpression of miR-16-5p r duces expression of regulators of cell cycle 
progression and apoptosis in glioma cells
MicroRNA target prediction showed that miR-16-5p has binding sites in the 3´-UTR of 
several genes that are involved in cell cycle progression and apoptosis. Most of these 
miR-16-5p targets have been validated by 3'-UTR luciferase assays in previous studies, 
including CDK6, CCND3, and CCNE1 (24, 25), CDC25A (26), WEE1, CHEK1 (27, 28), and 
BCL2 (25, 29). To investigate whether these targets are regulated by miR-16-5p in glioma 
cells, we transiently transfected A172 glioma cells with pre-miR-16-5p or pre-miR-NC. 
Overexpression of miR-16-5p resulted in significantly reduced mRNA expression of CDK6, 
CCND3, CCNE1, CDC25A, WEE1, and CHEK1 in A172 glioma cells (Fig. 3A). Levels of the 
respective proteins as well as BCL2 and MCL1 also were significantly reduced following 
miR-16-5p overexpression (Fig. 3B, C). Similar results were obtained in TP365MG and 
U251MG glioma cells (Suppl. Fig. 1). 































































MiR-16-5p directly binds to the 3´-UTRs of WEE1, CHEK1, and MCL1
To validate that miR-16-5p directly binds to the 3´-UTR of WEE1, CHEK1, and MCL1, we 
performed luciferase reporter assays using 3’-UTR fragments of each gene containing either 
the wildtype or mutated miR-16-5p binding sites. These experiments revealed specific 
binding of miR-16-5p to the 3’-UTR of all three genes (Fig. 4).
Expression of miR-16-5p target genes in astrocytic gliomas
To assess mRNA expression of the selected miR-16-5p target genes in glioma tissues, we 
referred to our published microarray data set (16), which showed that five of the eight 
investigated miR-16-5p targets (CDK6, WEE1, CHEK1, BCL2, and MCL1) showed 
significantly higher mRNA expression in anaplastic astrocytomas and/or glioblastomas when 
compared to non-neoplastic brain tissue (Fig. 5). 
Trichostatin A increases miR-16-5p expression in glioma cells
Involvement of DNA methylation and histone modifications have been implicated in the 
regulation of miR-16-5p in CLL (30) and non-small cell lung cancer (31). Therefore, we 
investigated whether treatment of A172, T98G, TP365MG, and U138MG glioma cells with 
the histone deacetylase inhibitor TSA had an impact on miR-16-5p expression. These 
experiments revealed significant up-regulation of miR-16-5p following TSA treatment in three 
of the four investigated cell lines (Fig. 6A). 
HDAC3 knock-down increases miR-16-5p expression in glioma cells
Previous studies in non-Hodgkin B-cell lymphomas and non-small cell lung cancers reported 
that MYC and HDAC3 co-localize to the promoters of the miR-15a/miR-16-1 cluster host 
gene DLEU2, and that inhibition of HDAC3 increases histone acetylation of these promoters 
(31, 32). To investigate whether a similar mechanism operates in glioma cells, we performed 































































knock-down experiments of HDAC3 in the glioma cell lines T98G and U251MG. Knock-down 
of HDAC3 (Fig. 6B, C) significantly increased expression of miR-16-5p relative to control-
transfected cells (Fig. 6D). We additionally investigated the expression of miR-16-5p target 
genes following HDAC3 knock-down and found that most of the miR-16-5p target genes, 
including CDK6, CCND3, CCNE1, CDC25A, WEE1, and CHEK1, were significantly down-
regulated following HDAC3 knock-down (Fig. 6 D, E), Supplementary Figure 3 shows the 
individual results obtained for expression of miR-16-5p and its target genes following HDAC3 
knock-down. 
Overexpression of miR-16-5p modulates the response of A172 glioma cells to 
irradiation and chemotherapy
To assess whether overexpression of miR-16-5p modulates the response of glioma cells to 
irradiation or TMZ, we performed cell survival assays on pre-miR-16-5p- versus pre-miR-NC-
transfected A172 and T98G glioma cells using radiation doses ranging from 1 to 9 Gy and 
TMZ concentrations ranging from 6.25 to 100 M in A172 and 150 to 1000 M in T98G cells 
(Fig. 7). A172 glioma cells are p53-wildtype glioma cells (33) that do not express 
O6-methylguanine DNA methyltransferase (MGMT) due to hypermethylation of the MGMT 
promoter (34). In contrast, T98G glioma cells are p53-mutant (33) and express MGMT (35). 
As reported (34), A172 cells showed higher sensitivity to TMZ treatment than T98G cells 
(Fig. 7A, B). Sensitivity to TMZ was significantly increased in pre-miR-16-5p-transfected as 
compared to control-transfected A172 glioma cells (Fig. 7A). Similarly, pre-miR-16-5p-
transfected A172 cells responded better to irradiation at clinically relevant radiation doses 
(Fig. 7C). In contrast, pre-miR-16-5p transfection did not modulate sensitivity of T98G cells to 
either TMZ treatment or irradiation (Fig. 7B, D).































































Relationship of miR-16-5p expression with IDH and TP53 mutation status as well as 
overall survival in the TCGA cohort
To investigate the relationship of miR-16-5p expression with IDH and TP53 mutation status 
as well as overall survival of glioblastoma patients, we interrogated TCGA data 
(http://cancergenome.nih.gov/). MiR-16-5p expression was lower in IDH-mutant than in IDH-
wildtype gliomas (Supplementary Fig. 2A), thus confirming findings in our institutional cohort 
(Fig. 1B). As the expression of miR-16-5p may be regulated by p53 (36, 37), we also 
interrogated the TCGA database for a relationship between TP53 mutation and miR-16-5p 
expression levels but found no association between these parameters (Suppl. Fig. 2B). 
MiR-16-5p expression was not linked to overall survival in 287 TCGA patients with 
glioblastomas, IDH-wildtype (WHO grade IV), when stratified according to high versus low 
expression levels (Suppl. Fig. 2C). Similarly, miR-16-5p expression was not prognostic in 
214 TCGA patients with diffuse or anaplastic astrocytomas, IDH-mutant (WHO grades II or 
III) (Suppl. Fig. 2D).
Discussion
In this study we report that expression of miR-16-5p is reduced in IDH-mutant astrocytic 
gliomas as well as a subset of IDH-wildtype glioblastomas relative to non-neoplastic brain 
tissue. Moreover, miR-16-5p expression is down-regulated in IDH-wildtype glioblastoma cell 
lines. MiR-16-5p was discovered as a deleted and down-regulated tumour suppressor 
candidate in B-cell CLL (14). Since then, numerous studies reported on deletion and/or 
reduced expression of this miRNA in various types of tumours, ranging from pituitary 
adenoma (38) to carcinomas of the prostate (39), lung (40), pancreas (41), stomach (42), 
breast (43), and ovaries (44), as well as other cancers (45). Several studies have also 
addressed expression of miR-16-5p in gliomas, with partly conflicting results. We originally 
reported that miR-16-5p was up-regulated upon progression of primary low-grade to 































































recurrent high-grade gliomas from individual patients (46). However, expression of 
miR-16-5p was significantly lower in primary and recurrent glioma tissues as compared to 
non-neoplastic brain tissue, a finding in line with our present data on a larger patient cohort. 
In contrast, Wuchty et al. (47) reported higher expression levels of miR-16-5p in primary 
glioblastomas as compared to normal brain tissue. This discrepancy might in part be 
explained by the use of different reference tissues and our finding that down-regulation of 
miR-16-5p is more frequent and stronger in IDH-mutant as compared to IDH-wildtype 
gliomas. Nevertheless, other authors also found increased levels of miR-16-5p, but not of its 
host gene DLEU2, in glioblastomas and oligodendrogliomas (48). In contrast, studies on 
glioma cell lines support a tumour suppressive role of miR-16-5p by demonstrating inhibitory 
effects of this miRNA on glioma cell proliferation, migration, invasion and epithelial-to-
mesenchymal transition, as well as stimulatory effects on apoptosis (49–53). Recent data 
additionally reported that miR-16-5p inhibits glioma stem cell clonogenicity and xenograft 
growth (25). In line, we found that miR-16-5p inhibited proliferation of three glioma cell lines 
(A172, TP365MG, T98G) and increased caspase-3/7 activity in two of these (A172, 
TP365MG). Studies on other cancers including CLL (29), oesophageal carcinoma (54), and 
non-small cell lung cancer (40), similarly reported on anti-proliferative and pro-apoptotic 
effects of miR-16-5p, thus establishing its tumour suppressive function. 
To investigate mechanisms causing inhibition of glioma growth by miR-16-5p, we 
investigated eight cell cycle and/or apoptosis regulatory genes that carry binding sites for 
miR-16-5p, i.e., CDK6, CCND3, CCNE1, CDC25A, WEE1, CHEK1, BCL2, and MCL1. 
Following transient transfection of miR-16-5p precursor molecules into different glioma cell 
lines, we found reduced expression of each of these genes at the mRNA and/or protein 
levels. Previous studies had already shown that miR-16-5p directly binds the 3´-UTR of 
CDK6, CCND3, CCNE1, CDC25A, and BCL2 (13, 24-26, 29, 39, 40, 51, 55, 56). Using 
3´-UTR luciferase reporter assays we confirmed its specific binding to the 3’-UTR of WEE1 
and CHEK1 (27, 28). Additional 3´-UTR luciferase reporter assays validated MCL1 as a 
direct miR-16-5p target. Taken together, these data suggest that reduced expression of 































































miR-16-5p may promote glioma growth by facilitating up-regulation of positive regulators of 
cell cycle progression (CDK6, CCND3, CCNE1, CDC25A) and inhibitors of apoptosis (BCL2, 
MCL1). Moreover, miR-16-5p down-regulation in glioma cells caused increased expression 
of WEE1 and CHEK1, which may contribute to cell survival by preventing mitotic catastrophe 
as a consequence of massive replication stress (57–59). 
MiR-16-5p overexpression may induce apoptosis by directly down-regulating BCL2 and 
MCL1 as originally reported in CLL (39, 60). In addition, overexpression of miR-16-5p 
activated the intrinsic apoptosis pathway via BCL2 in leukaemia cells (29). Former studies 
implicated BCL2 and MCL1 as important inhibitors of apoptosis also in glioma cells (61–65). 
Moreover, down-regulation of BCL2 and MCL1 by overexpression of another miRNA, miR-
153, has been reported to induce apoptosis of glioma cells (66). Thus, several lines of 
evidence accumulate to support the hypothesis that reduced expression of miR-16-5p may 
promote glioma cell survival by preventing apoptosis through facilitating up-regulation of 
BCL2 and MCL1. At the same time, miR-16-5p down-regulation may facilitate glioma cell 
proliferation due to enhanced G1/S phase transition caused by up-regulation of e.g. CDK6 
and CDC25A (25, 67, 68). 
In line with the in vitro data, we found significantly increased mRNA expression levels of the 
miR-16-5p target genes CDK6, WEE1, CHECK1, BCL2, and MCL1 in tissue samples of 
WHO grade III and/or WHO grade IV gliomas relative to non-neoplastic brain tissue, while no 
clear-cut up-regulation of CCNE1, CDC25A, and CCND3 was detected (16). Moreover, other 
studies reported on amplification and overexpression of CDK6 (69, 70), increased expression 
of MCL1 and BCL2 (71), as well as up-regulation of WEE1 and CHEK1 expression in 
malignant gliomas (58, 72). Similarly, CDC25A mRNA expression has been reported to 
increase along with the proliferation rate of gliomas (68). 
We also investigated potential mechanisms causing miR-16-5p down-regulation in gliomas. 
Studies on haematopoietic neoplasms showed that miR-16-5p expression may not only be 
reduced by copy number losses but also by epigenetic mechanisms, in particular histone 































































modifications (30–32). In B-cell lymphoma and lung carcinoma, transcription of DLEU2 and 
the miR-15a/miR-16-1 locus may be repressed by binding of MYC to DLEU2 promoter 
regions, followed by recruitment of HDAC3 (31, 32). We provide evidence that a similar 
mechanism may be active in glioma. We observed that TSA treatment of glioma cells 
increased miR-16-5p expression, supporting a role of histone modifications in its 
transcriptional down-regulation. In addition, we showed that siRNA-mediated knock-down of 
HDAC3 increased the expression of miR-16-5p with ensuing down-regulation of miR-16-5p 
target genes. 
MiR-16-5p and p53 have been reported to interact in a feedback circuitry loop in CLL, in 
which p53 transactivates transcription of the miRNA, while the miRNA down-regulates p53 
expression (27, 36, 60). Consequently, CLLs with TP53 alterations showed decreased levels 
of miR-16-5p as well as elevated MCL1 expression (60). Using TCGA glioma datasets, 
however, we found no association between TP53 mutation status and miR-16-5p expression, 
possibly due to the fact that astrocytic gliomas without TP53 mutation typically carry 
alterations in other p53 pathway genes, such as MDM2 or MDM4 amplification, or p14ARF 
homozygous deletion (73).
MiR-16-5p directly regulates the expression of several genes that have been linked to 
therapy resistance like BCL2, MCL1, WEE1, CHEK1, and CDK6 (58, 61, 74–77). In gliomas, 
miR-16 has been reported to modulate TMZ resistance in U251MG glioma cells by regulating 
BCL2 (78). In addition, miR-195, a member of the miR-15/miR-16 family, has been shown to 
inhibit glioma cell proliferation (79) and to modulate acquired resistance to TMZ (80). 
Moreover, members of the miR-15/miR-16 family have been linked to resistance against 
other drugs, including cisplatin, doxorubicin and 5-fluorouracil (28, 81, 82). Therefore, we 
addressed potential effects of miR-16-5p overexpression on the response of glioma cells to 
irradiation and TMZ. We investigated A172 and T98G glioma cells transfected either with 
miR-16-5p precursors or non-targeting control oligonucleotides for sensitivity to irradiation or 
TMZ in vitro. The two cell lines represented a p53-wildtype, MGMT promoter-methylated 































































model (A172) and a p53-mutant, MGMT promoter-unmethylated model (T98G). We found 
that miR-16-5p increased sensitivity to irradiation and TMZ treatment in A172 but not in 
T98G cells, with the latter cells also being resistant to spontaneous caspase-3/7 induction 
upon overexpression of miR-16-5p. With respect to miR-16-5p as a therapeutic target, as it is 
under investigation in prostate carcinoma and pleural mesothelioma (83, 84), our findings 
suggest that response to miR-16-5p expression in glioma might depend on the genetic 
background of the tumour cells. This hypothesis, however, would require further 
experimental evaluation. 
In TCGA data sets, we also addressed the question whether miR-16-5p expression is 
associated with overall survival of glioma patients. Expression of miR-16-5p was associated 
with overall survival in an institutional cohort of 132 glioblastoma patients (25). However, we 
found no prognostic role of high versus low miR-16-5p expression in 287 TCGA patients with 
IDH-wildtype glioblastoma and 214 TCGA patients with IDH-mutant diffuse or anaplastic 
astrocytomas. This discrepancy may be related to distinct patients cohorts, with the 
published cohort including younger patients (median age: 45 years) not specified for IDH 
status (25). In addition, different detection methods and miR-16-5p expression cut-offs were 
used. 
In summary, we report on frequent down-regulation of miR-16-5p expression in astrocytic 
gliomas relative to non-neoplastic brain tissue, with expression levels being lower in 
IDH-mutant as compared to IDH-wildtype gliomas. Treatment with TSA or genetic silencing 
of HDAC3 increased expression of miR-16-5p in glioma cells, suggesting a role of HDAC3-
mediated histone modification in the transcriptional regulation of miR-16-5p, as reported for 
other cancers (31, 32, 85). Overexpression of miR-16-5p in glioma cells reduced expression 
of CDK6, CDC25A, CCND3, CCNE1, WEE1, CHEK1, BCL2, and MCL1, decreased cell 
proliferation and increased caspase-3/7 activity. In addition, miR-16-5p overexpression in 
A172 glioma cells increased sensitivity to irradiation and temozolomide treatment. Thus, 
miR-16-5p down-regulation may support glioma growth by facilitating higher expression of 































































various proteins that promote cell cycle progression and cell survival and may also contribute 
to resistance to cytotoxic treatment of these tumours. 
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Legends to the figures
Figure 1. Expression of miR-16-5p in gliomas and glioma cell lines. (A, B) MiR-16-5p 
expression profiling using TaqMan® Array MicroRNA Cards in 9 non-neoplastic brain tissue 
(NB) and 79 gliomas including 7 diffuse astrocytomas, IDH-mutant, WHO grade II (AIImut), 10 
anaplastic astrocytomas, IDH-mutant, WHO grade III (AAIIImut), 10 glioblastomas, IDH-
mutant, WHO grade IV (GBIVmut), and 52 glioblastomas, IDH-wildtype, WHO grade IV 
(GBIVwt). Box plots indicate normalized median expression values as well as lower and upper 
quartiles. Whiskers indicate lowest and highest expression levels. (A) Glioma groups were 
compared to the NB group by ANOVA and Dunnett's post hoc test. (B) 52 IDH-wildtype were 
compared to 27 IDH-mutant gliomas using two-sided unpaired Student´s t-test (C) MiR-16-5p 
expression as determined by targeted realtime RT-PCR. Six glioma cell lines (A172, T98G, 
TP365MG, U138MG, U87MG, U251MG, abbreviated as CL) were compared to ten non-
neoplastic brain tissue samples (NB) using two-sided unpaired Student´s t-test. In all graphs, 
asterisks indicate significant expression differences (*, p < 0.05; **, p < 0.01; 
****, p < 0.0001).
Figure 2. Decreased viability and proliferation as well as increased caspase-3/7 
activity following overexpression of miR-16-5p in glioma cells. Glioma cells were 
transiently transfected with 25 nM (viability and proliferation) or 50 nM (caspase-3/7 activity) 
pre-miR-16-5p or pre-miR-NC controls for 72 hours. Graphs depict cell viability (A), 
proliferation (B) and caspase-3/7 activity (C) for the cell lines A172, TP98G, and TP365MG. 
Dots represent the mean of 5 replicate measurements. Three independent experiments were 
performed per cell line. P-values are calculated using a mixed model. For calculations, the 
fixed variable was the transfection group and the random variable was the week of 
transfection. RLU, relative luminescence units; RFU, relative fluorescence units.































































Figure 3. MRNA expression and protein levels of selected miR-16-5p target genes 
following transfection of miR-16-5p precursors in A172 glioma cells. (A) Shown are 
results of realtime-RT-PCR expression analyses using ARF1 as reference transcript. Three 
independent experiments were performed. P-values refer to two-sided paired Student´s t-
tests. Note reduced expression of CDK6, CCND3, CCNE1, CDC25A, WEE1, and CHEK1 but 
not BCL2 and MCL1 transcripts after miR-16-5p overexpression. Exemplary results of 
Western blot analyses (B) and its quantifications (C) in A172 glioma cells transiently 
transfected with pre-miR-16-5p or pre-miR-NC are shown. Blots were immunostained for ß-
actin (ACTB) to normalize the protein levels in the individual lanes. Note that all eight target 
proteins, including BCL2 and MCL1, were down-regulated by miR-16-5p overexpression 
relative to control transfected cells (B, C). 
Figure 4. Demonstration of direct binding of miR-16-5p to the 3'-UTRs of WEE1, 
CHEK1, and MCL1 using luciferase reporter assay. (A) Schematic representation of 
miR-16-5p binding sites in the 3'-UTR of the target genes WEE1, CHEK1, MCL1 that were 
cloned into psiCHECK-2TM plasmids with flanking nucleotides. Bold bases represent bases 
comprising the recognition sites for the miRNA seed sequence that were mutated (mut, 
mut1, mut2, mut1,2) to ensure specific miRNA binding. (B) T98G glioma cells were 
transiently co-transfected with either 100 ng WEE1, CHEK1 or MCL1 wildtype (wt) or 
mutated 3´-UTR reporter constructs and 50 nM pre-miR-16-5p or pre-miR-NC for 72 hours 
(WEE1) or 48 hours (CHEK1 and MCL1). Bars and error bars represent the mean results of 
three independent experiments and standard errors of the mean. Each experiment 
comprised 5 replicates. P-values refer to two-sided, paired Student´s t-tests (*, p < 0.05; 
***, p < 0.001). RLU, relative luminescence units.
Figure 5. MRNA expression of several miR-16-5p target genes in gliomas. Results of 
microarray expression analyses of four non-neoplastic brain tissue (NB) and 68 human 
gliomas, including 8 AIImut, 10 AAIIImut, 11 GBIVmut, and 39 GBIVwt are shown. Box plots are 































































depicted indicating median expression as well as lower and upper quartiles. Whiskers 
indicate lowest and highest expression values. Comparison between each tumour group and 
the non-neoplastic brain tissue group (NB) was performed by ANOVA and Dunnett's post hoc 
test. Asterisks indicate significant expression differences (*, p < 0.05; **, p < 0.01; 
***, p < 0.001). 
Figure 6. Treatment with trichostatin A (TSA) as well as siRNA-mediated HDAC3 
knockdown increases miR-16-5p expression in glioma cells. (A) Glioma cells were 
treated with 1 µM TSA for 36 hours. Shown are real-time RT-PCR results for miR-16-5p in 
A172, T98G, TP365MG, and U138MG cells. Each dot represents data from two technical 
replicates. Three independent experiments were performed. (B-D) Results of HDAC3 
knockdown in T98G and U251MG glioma cells. Transfection of two siRNAs against HDAC3 
(si_HDAC3-1, si_HDAC3-2) effectively reduced HDAC3 at the mRNA (B) and protein level 
(C) as compared to control transfected cells (si_NC). ARF1 was used to normalize mRNA 
expression and ACTB to normalize protein expression. HDAC3 knockdown resulted in 
significantly increased expression (black squares) of miR-16-5p as well as significantly 
reduced expression (white squares) of most of the investigated miR-16-5p target genes. 
Three independent transfections were performed. P-values were calculated using the two-
sided, paired Student´s t-test (*, p < 0.05; ** p < 0.01). 
Figure 7. Modulation of glioma cell sensitivity to irradiation and temozolomide 
treatment by transfection of miR-16-5p precursors. Pre-miR-16-5p-transfected (black 
squares) or pre-miR-NC control-transfected (open circles) A172 cells (A, C) or T98G cells (B, 
D) were exposed to increasing concentrations of TMZ for 24 h (A, B) or irradiated at 
increasing doses (C, D) and allowed to grow for 2-3 weeks in complete medium. Cell density 
was assessed by crystal violet staining. Data were assessed in triplets. Shown are diagrams 
of one of three independent replica experiments each (*, p < 0.05; **, p < 0.01; ***, p < 0.001, 
two-sided student's T-test). 































































Figure 1. Expression of miR-16-5p in gliomas and glioma cell lines. (A, B) MiR-16-5p expression profiling 
using TaqMan® Array MicroRNA Cards in 9 non-neoplastic brain tissue (NB) and 79 gliomas including 7 
diffuse astrocytomas, IDH-mutant, WHO grade II (AIImut), 10 anaplastic astrocytomas, IDH-mutant, WHO 
grade III (AAIIImut), 10 glioblastomas, IDH-mutant, WHO grade IV (GBIVmut), and 52 glioblastomas, IDH-
wildtype, WHO grade IV (GBIVwt). Box plots indicate normalized median expression values as well as lower 
and upper quartiles. Whiskers indicate lowest and highest expression levels. (A) Glioma groups were 
compared to the NB group by ANOVA and Dunnett's post hoc test. (B) 52 IDH-wildtype were compared to 
27 IDH-mutant gliomas using two-sided unpaired Student´s t-test (C) MiR-16-5p expression as determined 
by targeted realtime RT-PCR. Six glioma cell lines (A172, T98G, TP365MG, U138MG, U87MG, U251MG, 
abbreviated as CL) were compared to ten non-neoplastic brain tissue samples (NB) using two-sided unpaired 
Student´s t-test. In all graphs, asterisks indicate significant expression differences (*, p < 0.05; **, p < 
0.01; ****, p < 0.0001). 
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Figure 2. Decreased viability and proliferation as well as increased caspase-3/7 activity following 
overexpression of miR-16-5p in glioma cells. Glioma cells were transiently transfected with 25 nM (viability 
and proliferation) or 50 nM (caspase-3/7 activity) pre miR 16-5p or pre-miR-NC controls for 72 hours. 
Graphs depict cell viability (A), proliferation (B) and caspase-3/7 activity (C) for the cell lines A172, TP98G, 
and TP365MG. Dots represent the mean of 5 replicate measurements. Three independent experiments were 
performed per cell line. P-values are calculated using a mixed model. For calculations, the fixed variable was 
the transfection group and the random variable was the week of transfection. RLU, relative luminescence 
units; RFU, relative fluorescence units 
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Figure 3. MRNA expression and protein levels of selected miR-16-5p target genes following transfection of 
miR-16-5p precursors in A172 glioma cells. (A) Shown are results of realtime-RT-PCR expression analyses 
using ARF1 as reference transcript. Three independent experiments were performed. P-values refer to two-
sided paired Student´s t-tests. Note reduced expression of CDK6, CCND3, CCNE1, CDC25A, WEE1, and 
CHEK1 but not BCL2 and MCL1 transcripts after miR-16-5p overexpression. Exemplary results of Western 
blot analyses (B) and its quantifications (C) in A172 glioma cells transiently transfected with pre-miR-16-5p 
or pre-miR-NC are shown. Blots were immunostained for ß-actin (ACTB) to normalize the protein levels in 
the individual lanes. Note that all eight target proteins, including BCL2 and MCL1, were down-regulated by 
miR-16-5p overexpression relative to control transfected cells (B, C). 
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Figure 4. Demonstration of direct binding of miR-16-5p to the 3'-UTRs of WEE1, CHEK1, and MCL1 using 
luciferase reporter assay. (A) Schematic representation of miR 16 5p binding sites in the 3'-UTR of the 
target genes WEE1, CHEK1, MCL1 that were cloned into psiCHECK-2TM plasmids with flanking nucleotides. 
Bold bases represent bases comprising the recognition sites for the miRNA seed sequence that were 
mutated (mut, mut1, mut2, mut1,2) to ensure specific miRNA binding. (B) T98G glioma cells were 
transiently co-transfected with either 100 ng WEE1, CHEK1 or MCL1 wildtype (wt) or mutated 3´-UTR 
reporter constructs and 50 nM pre-miR-16-5p or pre-miR-NC for 72 hours (WEE1) or 48 hours (CHEK1 and 
MCL1). Bars and error bars represent the mean results of three independent experiments and standard 
errors of the mean. Each experiment comprised 5 replicates. P-values refer to two-sided, paired Student´s 
t-tests (*, p < 0.05; ***, p < 0.001). RLU, relative luminescence units. 
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Figure 5. MRNA expression of several miR-16-5p target genes in gliomas. Results of microarray expression 
analyses of four non-neoplastic brain tissue (NB) and 68 human gliomas, including 8 AIImut, 10 AAIIImut, 
11 GBIVmut, and 39 GBIVwt are shown. Box plots are depicted indicating median expression as well as 
lower and upper quartiles. Whiskers indicate lowest and highest expression values. Comparison between 
each tumour group and the non-neoplastic brain tissue group (NB) was performed by ANOVA and Dunnett's 
post hoc test. Asterisks indicate significant expression differences (*, p < 0.05; **, p < 0.01; ***, p < 
0.001). 
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Figure 6. Treatment with trichostatin A (TSA) as well as siRNA-mediated HDAC3 knockdown increases miR-
16-5p expression in glioma cells. (A) Glioma cells were treated with 1 µM TSA for 36 hours. Shown are real-
time RT-PCR results for miR-16-5p in A172, T98G, TP365MG, and U138MG cells. Each dot represents data 
from two technical replicates. Three independent experiments were performed. (B-D) Results of HDAC3 
knockdown in T98G and U251MG glioma cells. Transfection of two siRNAs against HDAC3 (si_HDAC3-1, 
si_HDAC3-2) effectively reduced HDAC3 at the mRNA (B) and protein level (C) as compared to control 
transfected cells (si_NC). ARF1 was used to normalize mRNA expression and ACTB to normalize protein 
expression. HDAC3 knockdown resulted in significantly increased expression (black squares) of miR-16-5p 
as well as significantly reduced expression (white squares) of most of the investigated miR-16-5p target 
genes. Three independent transfections were performed. P-values were calculated using the two-sided, 
paired Student´s t-test (*, p < 0.05; ** p < 0.01). 
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Figure 7. Modulation of glioma cell sensitivity to irradiation and temozolomide treatment by transfection of 
miR-16-5p precursors. Pre-miR-16-5p-transfected (black squares) or pre-miR-NC control-transfected (open 
circles) A172 cells (A, C) or T98G cells (B, D) were exposed to increasing concentrations of TMZ for 24 h (A, 
B) or irradiated at increasing doses (C, D) and allowed to grow for 2-3 weeks in complete medium. Cell 
density was assessed by crystal violet staining. Data were assessed in triplets. Shown are diagrams of one 
of three independent replica experiments each (*, p < 0.05; **, p < 0.01; ***, p < 0.001, two-sided 
student's T-test). 
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Supplementary Table 1. Overview of primer sequences used for (1) qRT-PCR, (2, 3) 
luciferase reporter gene assay (2: with the wildtype binding sequence, and 3: with the mutated 
binding site for miR-16-5p). 































































Gene Accession-No. Chromosome Primer sequence Remarks Amplicon 
length
Application





















































































































































Supplementary Figure 1. Decreased expression of selected target genes following 
transfection of miR-16-5p precursors in TP365MG and U251MG glioma cells. (A, C) Results 































































of qRT-PCR expression analyses using ARF1 as reference. Three independent experiments 
were performed. P-values refer to two-sided paired Student´s t-tests. (B, D) Quantification of 
Western blot analyses. Blots were immunostained for beta-actin (ACTB) to normalize protein 
levels in the individual lanes. 































































Supplementary Figure 2. Results based on correlative analyses of TCGA data sets, (A) 
Lower expression of miR-16-5p in IDH-mutant (IDH mut, n=365) as compared to IDH-wildtype 
gliomas from the TCGA-LGG dataset (IDH wt, n= 86). (B) MiR-16-5p expression does not differ 
between TP53-wildtype and TP53-mutant IDH-wildtype glioblastomas (n=141). (C-D) MiR-16-5p 
expression is not linked to overall survival in IDH-wildtype glioblastoma patients (n = 287) (C) 
and in IDH-mutant diffuse and anaplastic astrocytoma patients (n=214) (D).































































Supplementary Figure 3. Increased expression of miR-16-5p and reduced expression of 
its target genes in T98G and U251MG glioma cells following HDAC3 knock-down. Results 
of qRT-PCR using U6 snRNA as reference for miRNA expression analysis and ARF1 as 
reference gene for mRNA expression analysis in T98G or U251MG cells transiently transfected 
with 50 nM siRNA against HDAC3. Three independent experiments were performed. P-values 
refer to two-sided paired Student´s t-tests. 
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